The honest answer is that no one knows for certain what causes encephalitis lethargica. Despite a century of research, the exact trigger behind this devastating brain inflammation has never been conclusively identified. What scientists do have are three leading theories: a link to influenza, a connection to streptococcal bacteria, and an autoimmune process in which the body’s immune system attacks its own brain tissue. Modern evidence increasingly points toward that autoimmune mechanism, but the original trigger that sets it in motion remains elusive.
Why the Original Cause Was Never Found
Encephalitis lethargica first appeared around 1917 and swept through populations worldwide over the next decade, leaving roughly a million people affected before it largely vanished by the late 1920s. Throughout the 1920s, researchers investigated the disease intensively but could never pin down a single pathogen. By the time cases faded, two camps had formed: one blamed the herpes virus, the other blamed streptococcal infection. Ironically, a third theory gained dominance after the epidemic ended, despite being considered the least likely explanation by 1930. That theory held that encephalitis lethargica was caused by a particularly brain-targeting form of the influenza virus.
The influenza hypothesis was popular early on because both diseases emerged around the same time, and the 1918 flu pandemic killed tens of millions worldwide. It seemed logical that a virus capable of such destruction might also attack the brain. But the timing never quite lined up. Cases of encephalitis lethargica appeared before the worst waves of the flu, persisted long after influenza receded, and many patients had no history of flu infection at all.
Modern Testing Rules Out Influenza
The influenza theory received its most definitive challenge when researchers at the Armed Forces Institute of Pathology examined preserved brain tissue from five patients who died during the acute phase of the epidemic and two who later developed post-encephalitic Parkinson’s disease. Using modern genetic amplification techniques to search for influenza RNA in 38 tissue samples, they found nothing. Every sample came back negative for influenza genetic material. This makes it unlikely that the 1918 influenza virus was directly responsible for encephalitis lethargica by infecting brain tissue.
That finding didn’t completely sever the connection between flu and encephalitis lethargica. It’s still possible that influenza triggered an immune response that then turned against the brain, even if the virus itself never reached it. But as a direct cause, influenza appears to be ruled out.
The Autoimmune Theory
The strongest evidence in modern cases points to an autoimmune process centered on the basal ganglia, a cluster of structures deep in the brain that help control movement, emotions, and behavior. In a landmark study of 20 patients with encephalitis lethargica, 95% had antibodies in their blood that attacked proteins in the basal ganglia. Their immune systems were treating their own brain tissue as a foreign invader.
This pattern resembles what happens in other post-infectious brain diseases. When Group A Streptococcus (the bacterium behind strep throat) infects the body, the immune system produces antibodies to fight it. But certain proteins on the surface of strep bacteria share a structural resemblance to proteins on human brain cells, a phenomenon called molecular mimicry. The antibodies meant for the bacteria mistakenly latch onto brain tissue instead, particularly in the basal ganglia. The specific targets appear to be enzymes on the surface of neurons involved in energy metabolism, cell signaling, and communication between nerve cells. When those enzymes are disrupted, movement disorders and psychiatric symptoms follow.
Pathology studies consistently show inflammatory immune cells infiltrating the brain, with the basal ganglia taking the heaviest damage. This pattern of inflammation explains why the disease so reliably produces movement problems, sleep disruption, and behavioral changes.
What Happens in the Brain
The inflammation in encephalitis lethargica doesn’t strike randomly. It targets specific brain regions with remarkable consistency. The basal ganglia are the primary victims, which accounts for the hallmark movement disorders. The substantia nigra, a small structure in the midbrain that produces dopamine, is also vulnerable. When neurons in the substantia nigra die, dopamine production drops, and parkinsonian symptoms develop: rigidity, slowed movement, and postural instability.
Researchers studying brain tissue from encephalitis lethargica patients have found signs of “pigmentary incontinence” in the substantia nigra. Normally, cells in this region contain dark pigment. When those cells die, the pigment spills out, leaving a visible record of destruction. Notably, this damage appears to occur through a different biological pathway than typical Parkinson’s disease, suggesting encephalitis lethargica carves its own distinct path of destruction through the brain.
Women who were in their late teens and twenties during the height of the epidemic, the age group most susceptible to clinical illness, showed a greater risk of substantia nigra degeneration and Parkinson’s features later in life. Whatever the original insult was, it could set the stage for neurological decline decades later.
Symptoms and How It Progresses
The acute phase of encephalitis lethargica typically involves a sudden or subacute onset of brain inflammation. Motor symptoms appear in roughly 98% of cases, cranial nerve problems in 91%, eye movement abnormalities in 77%, and sleep disorders in 66%. Psychiatric features, including obsessive-compulsive behavior and psychosis, show up in about 54% of patients. The formal diagnostic criteria require at least three of seven features: basal ganglia involvement, oculogyric crises (involuntary upward eye movements), eye muscle paralysis, obsessive-compulsive behavior, a mute and motionless state, central breathing irregularities, and excessive sleepiness or inverted sleep cycles.
Severe sleep disturbances, either uncontrollable drowsiness or total insomnia, follow rapidly and can last weeks. The disease gets its name from the profound lethargy that overtakes many patients, sometimes to the point of near-coma.
The acute phase isn’t the end. Between one and five years after the initial illness, many patients develop a slowly progressive parkinsonian syndrome. These post-encephalitic Parkinson’s symptoms differ from typical Parkinson’s disease in several ways. They tend to strike younger people, including children and adults aged 25 to 40. The classic resting tremor of Parkinson’s disease is relatively rare. Instead, patients experience rigidity, difficulty initiating movement, postural instability, and speech problems. The progression happens in discontinuous spurts rather than the steady decline seen in ordinary Parkinson’s, and parkinsonian symptoms can persist for 17 to 33 years. Many patients also develop visual hallucinations, paranoid psychosis, memory deficits, and problems with attention and impulse control.
Treatment Challenges
Oliver Sacks famously documented the use of levodopa (a dopamine-replacing drug) in post-encephalitic patients at a chronic care hospital in the late 1960s. Many of these patients had been essentially frozen for decades. High doses of levodopa produced dramatic initial awakenings, with patients suddenly able to move and speak again. But the improvements were almost always temporary. Most patients relapsed and developed severe complications including involuntary movements, hallucinations, psychosis, and insomnia. Of the 20 patients Sacks treated, 17 died within nine years.
For modern sporadic cases, treatment depends on whether an autoimmune mechanism can be identified. When antibodies against brain tissue are found, immunotherapies such as corticosteroids or intravenous immunoglobulin have shown some benefit, though responses are variable and often delayed. In cases linked to specific antibodies against nerve cell receptors, removing an associated tumor (when present) combined with immune-suppressing treatment has produced improvement.
Does Encephalitis Lethargica Still Exist?
Sporadic cases matching the clinical profile of encephalitis lethargica continue to appear, though rarely. These modern cases raise an important question: are they truly the same disease that swept the world a century ago, or are they better classified as a form of autoimmune encephalitis that happens to produce similar symptoms? Some researchers have argued the term “encephalitis lethargica” should be retired for these sporadic cases and replaced with more precise autoimmune diagnoses.
This isn’t just an academic debate. At least two patients initially diagnosed with encephalitis lethargica were later found to have antibodies against a specific brain receptor called the NMDA receptor, a well-characterized and treatable form of autoimmune encephalitis. That distinction carries real consequences: NMDA receptor encephalitis can be associated with tumors that need removal, and targeted immune treatments can be highly effective. A diagnosis of encephalitis lethargica, by contrast, offers little treatment guidance. The triggers for these sporadic cases are thought to be infections, environmental exposures, or genetic susceptibility, but in most instances no specific cause is identified.
What remains clear is that the original epidemic-scale disease involved a chain of events starting with some infectious trigger, probably bacterial rather than viral, that provoked an immune assault on the brain’s movement and sleep centers. The precise identity of that trigger, and why it appeared so suddenly and disappeared so completely, remains one of neurology’s most enduring mysteries.